{"id":69525,"date":"2026-07-07T20:49:49","date_gmt":"2026-07-07T12:49:49","guid":{"rendered":"https:\/\/flcube.com\/?p=69525"},"modified":"2026-07-07T20:50:39","modified_gmt":"2026-07-07T12:50:39","slug":"cstone-pharmaceuticals-partners-with-arrotex-for-sugemalimab-commercialization-across-australia-and-new-zealand","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69525","title":{"rendered":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CStone Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>) announced an <strong>exclusive commercialization partnership<\/strong> with <strong>Arrotex Pharmaceuticals Pty Ltd<\/strong>, the core pharmaceutical commercialization platform of Australia&#8217;s leading integrated healthcare group <strong>DBG Health (DBG)<\/strong>, for <strong>sugemalimab<\/strong> across <strong>Australia<\/strong> and <strong>New Zealand<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-commercial-framework\" class=\"wp-block-heading\">Deal Structure &amp; Commercial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>CStone Pharmaceuticals (HKG: 2616) and Arrotex Pharmaceuticals (DBG Health subsidiary)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sugemalimab (anti-PD-L1 monoclonal antibody)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Australia and New Zealand<\/td><\/tr><tr><td><strong>Indications Covered<\/strong><\/td><td>All current and future approved indications: Stage III\/IV NSCLC, gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), extranodal NK\/T-cell lymphoma (ENKTL)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + regulatory and sales milestone payments + revenue sharing<\/td><\/tr><tr><td><strong>Supply Responsibility<\/strong><\/td><td>CStone responsible for product supply to Arrotex<\/td><\/tr><tr><td><strong>Commercial Rights<\/strong><\/td><td>Arrotex holds exclusive commercialization rights including regulatory filings and promotional activities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-indication-portfolio\" class=\"wp-block-heading\">Product Profile &amp; Indication Portfolio<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Anti-PD-L1 monoclonal antibody<\/li>\n\n\n\n<li><strong>Approved Indications:<\/strong><\/li>\n\n\n\n<li><strong>Stage III non-small cell lung cancer (NSCLC)<\/strong> \u2013 consolidation therapy post-chemoradiation<\/li>\n\n\n\n<li><strong>Stage IV NSCLC<\/strong> \u2013 first-line combination therapy<\/li>\n\n\n\n<li><strong>Gastric cancer (GC)<\/strong> \u2013 advanced\/metastatic setting<\/li>\n\n\n\n<li><strong>Esophageal squamous cell carcinoma (ESCC)<\/strong> \u2013 locally advanced or metastatic disease<\/li>\n\n\n\n<li><strong>Extranodal NK\/T-cell lymphoma (ENKTL)<\/strong> \u2013 relapsed\/refractory setting<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Established immuno-oncology agent with multiple regulatory approvals in China and Asia-Pacific regions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-rationale\" class=\"wp-block-heading\">Strategic Partnership Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>CStone Pharmaceuticals<\/strong><\/td><td>Expands international footprint into developed markets without establishing local commercial infrastructure; leverages DBG Health&#8217;s integrated healthcare ecosystem for optimal market access<\/td><\/tr><tr><td><strong>Arrotex Pharmaceuticals\/DBG Health<\/strong><\/td><td>Diversifies oncology portfolio with premium immuno-oncology asset; strengthens position in rapidly growing PD-(L)1 inhibitor market across ANZ region<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">DBG Health represents Australia&#8217;s leading integrated healthcare group with comprehensive capabilities spanning hospitals, pharmacies, diagnostic services, and pharmaceutical distribution, providing Arrotex with unparalleled market access and patient reach.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ANZ Immuno-Oncology Market:<\/strong> Combined market valued at AUD 1.2 billion ($820 million) in 2025, dominated by established PD-(L)1 inhibitors including Keytruda, Opdivo, and Tecentriq<\/li>\n\n\n\n<li><strong>NSCLC Opportunity:<\/strong> Australia diagnoses approximately 14,000 new lung cancer cases annually, with NSCLC representing 85% of cases<\/li>\n\n\n\n<li><strong>Gastric Cancer Burden:<\/strong> New Zealand has one of the highest gastric cancer incidence rates globally, creating significant unmet need<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Sugemalimab&#8217;s approval in ENKTL \u2013 a rare but aggressive lymphoma with limited treatment options \u2013 provides niche market exclusivity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-amp-commercial-strategy\" class=\"wp-block-heading\">Regulatory &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Arrotex will lead all regulatory submissions to Australia&#8217;s Therapeutic Goods Administration (TGA) and New Zealand&#8217;s Medsafe<\/li>\n\n\n\n<li><strong>Pricing &amp; Reimbursement:<\/strong> Strategy will focus on Pharmaceutical Benefits Scheme (PBS) listing in Australia and Pharmac funding in New Zealand<\/li>\n\n\n\n<li><strong>Launch Sequencing:<\/strong> Initial focus likely on NSCLC indications given larger patient populations and established reimbursement pathways<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> DBG Health&#8217;s integrated model enables coordinated approach across hospital, community, and specialty pharmacy channels<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the CStone-Arrotex partnership, regulatory submissions, commercial launch timelines, and market penetration expectations. Actual results may differ due to risks including regulatory approvals, pricing negotiations, competitive dynamics, and market adoption rates in the ANZ oncology landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4657,16,188,856,18],"class_list":["post-69525","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-arrotex-pharmaceuticals","tag-cancer","tag-cstone-pharmaceuticals","tag-hkg-2616","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia&#039;s leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69525\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand\" \/>\n<meta property=\"og:description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia&#039;s leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69525\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T12:49:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T12:50:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand\",\"datePublished\":\"2026-07-07T12:49:49+00:00\",\"dateModified\":\"2026-07-07T12:50:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Arrotex Pharmaceuticals\",\"Cancer\",\"CStone Pharmaceuticals\",\"HKG: 2616\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69525#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69525\",\"name\":\"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T12:49:49+00:00\",\"dateModified\":\"2026-07-07T12:50:39+00:00\",\"description\":\"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia's leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69525\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69525#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand - Insight, China&#039;s Pharmaceutical Industry","description":"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia's leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69525","og_locale":"en_US","og_type":"article","og_title":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand","og_description":"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia's leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.","og_url":"https:\/\/flcube.com\/?p=69525","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T12:49:49+00:00","article_modified_time":"2026-07-07T12:50:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69525#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69525"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand","datePublished":"2026-07-07T12:49:49+00:00","dateModified":"2026-07-07T12:50:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69525"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Arrotex Pharmaceuticals","Cancer","CStone Pharmaceuticals","HKG: 2616","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69525#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69525","url":"https:\/\/flcube.com\/?p=69525","name":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T12:49:49+00:00","dateModified":"2026-07-07T12:50:39+00:00","description":"CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the core pharmaceutical commercialization platform of Australia's leading integrated healthcare group DBG Health (DBG), for sugemalimab across Australia and New Zealand.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69525#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69525"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69525#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69525"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69525\/revisions"}],"predecessor-version":[{"id":69528,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69525\/revisions\/69528"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}